Last reviewed · How we verify
Acriflavine (euflavine)
Acriflavine (generic name: euflavine) is a euflavine drug. It is currently in unknown development.
Acriflavine works by binding to and inhibiting hypoxia-inducible factor 1-alpha, a protein that helps cells adapt to low oxygen levels.
Acriflavine is an antiseptic and disinfectant, as classified by Wikipedia. It is being studied in combination with other treatments for urinary tract infections, specifically in the clinical trial "Clinical Assessment of Urinary Antiseptics Methenamine and Methylthioninium in Recurrent Cystitis" (NCT03379389).
At a glance
| Generic name | euflavine |
|---|---|
| Drug class | euflavine |
| Target | Hypoxia-inducible factor 1-alpha, ORF 73 |
| Therapeutic area | Oncology |
| Phase | unknown |
Mechanism of action
Think of hypoxia-inducible factor 1-alpha like a switch that helps cells survive in low-oxygen environments. Acriflavine turns off this switch, which can help prevent the growth of certain types of cancer cells that thrive in low-oxygen conditions.
Approved indications
Common side effects
Key clinical trials
- Clinical Assessment of Urinary Antiseptics Methenamine and Methylthioninium in Recurrent Cystitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acriflavine CI brief — competitive landscape report
- Acriflavine updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Acriflavine
What is Acriflavine?
How does Acriflavine work?
What is the generic name of Acriflavine?
What drug class is Acriflavine in?
What development phase is Acriflavine in?
What does Acriflavine target?
Related
- Drug class: All euflavine drugs
- Target: All drugs targeting Hypoxia-inducible factor 1-alpha, ORF 73
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing